Who Is Strut Best For? Ideal Patient Profile, Costs, and Clinical Evidence

What Strut Actually Offers

Strut Health operates as a direct-to-consumer telehealth platform paired with a compounding pharmacy. Patients complete an online questionnaire, a licensed provider reviews the submission asynchronously, and prescriptions ship directly. The model eliminates in-person visits for conditions that typically follow well-established treatment algorithms.

The three clinical verticals are androgenetic alopecia (AGA), dermatologic conditions (primarily acne and photoaging), and erectile dysfunction (ED). Each vertical uses compounded formulations that combine two or more active pharmaceutical ingredients into a single topical or oral product. Compounded medications are prepared under state pharmacy board oversight but are not individually evaluated by the FDA for safety and efficacy the way commercially manufactured drugs are [1]. This distinction matters. The individual ingredients carry strong clinical data, but the specific combinations and vehicles Strut uses have not undergone the randomized controlled trials required for FDA approval of a finished product.

Strut's model works when a patient's diagnosis is straightforward and the treatment protocol is guideline-concordant. It works less well when a condition requires physical examination, laboratory monitoring, or iterative dose titration under close supervision.

The Hair Loss Patient: Mild-to-Moderate AGA

The strongest clinical case for Strut's hair formulations applies to adults with Norwood stage II through IV androgenetic alopecia who want a topical alternative to oral finasteride. Strut's flagship hair product combines topical finasteride with minoxidil.

Oral finasteride at 1 mg daily remains the reference standard. A five-year extension of the original key trial demonstrated that 65% of men on finasteride 1 mg showed increased hair counts versus baseline, compared to a continued decline in the placebo group [2]. Topical finasteride aims to deliver the same 5-alpha-reductase inhibition with lower systemic exposure. A 2022 phase III trial (N=458) found that topical finasteride 0.25% applied once daily produced statistically significant improvements in target-area hair count versus vehicle at 26 weeks, with serum DHT suppression roughly 25-30% compared to 60-70% suppression seen with oral finasteride [3].

Topical minoxidil 5% is itself well-supported. A 48-week randomized trial (N=393) showed 5% topical minoxidil produced a mean change of +18.6 hairs/cm² versus +12.7 for the 2% formulation in men with AGA [4]. The American Academy of Dermatology guidelines recommend both minoxidil and finasteride as first-line options for AGA [5].

Who fits: Men aged 18-50 with diffuse vertex thinning or frontal recession (Norwood II-IV), no history of finasteride hypersensitivity, and a preference for topical over oral medication. Women with female-pattern hair loss (Ludwig I-II) may benefit from minoxidil-only formulations but should avoid finasteride-containing products during reproductive years due to teratogenicity risk.

Who does not fit: Patients with Norwood V+ or near-complete vertex baldness should set realistic expectations. Dr. Antonella Tosti, a dermatology professor at the University of Miami Miller School of Medicine, has noted: "Finasteride and minoxidil stabilize hair loss and produce modest regrowth, but they cannot restore a full head of hair in advanced cases. Patients with significant miniaturization often need procedural interventions like hair transplantation alongside medical therapy." Individuals with unexplained alopecia, scarring patterns, or suspected alopecia areata need in-person evaluation and biopsy before starting any DTC protocol.

The Skin Patient: Acne and Anti-Aging

Strut's dermatology formulations center on tretinoin-based compounded creams, sometimes combined with niacinamide, clindamycin, or topical spironolactone. The clinical evidence for each ingredient individually is extensive.

Tretinoin is the most-studied topical retinoid. A Cochrane systematic review of 12 RCTs involving over 2,700 participants confirmed that topical tretinoin significantly reduces fine wrinkles, mottled hyperpigmentation, and roughness compared to vehicle over 12-48 weeks [6]. For acne, the combination of a topical retinoid plus a topical antibiotic (such as clindamycin) is recommended as first-line therapy for moderate inflammatory acne by the American Academy of Dermatology's 2024 guidelines [7].

Topical spironolactone (compounded, typically 5%) represents a newer approach for hormonal acne in women. Oral spironolactone at 50-200 mg/day has demonstrated acne clearance rates of 50-100% across multiple retrospective studies [8]. The topical route theoretically reduces systemic anti-androgen side effects (hyperkalemia, menstrual irregularities), though large RCTs of topical spironolactone for acne are still limited in number.

Who fits: Adults with mild-to-moderate comedonal or inflammatory acne, photoaging concerns, or both, who have no contraindications to retinoids and want a single multi-ingredient product. Patients who have tried OTC retinol or adapalene without adequate results are reasonable candidates for prescription-strength tretinoin delivered via a telehealth model.

Who does not fit: Severe nodulocystic acne that may require isotretinoin demands in-person management with monthly labs (pregnancy testing, lipid panels, liver enzymes) per the iPLEDGE REMS program [9]. Patients with rosacea are sometimes misclassified as having acne, and tretinoin can worsen rosacea-related erythema. A visual examination (even via synchronous telemedicine) is preferable to an asynchronous questionnaire for ambiguous presentations.

The ED Patient: PDE5 Inhibitor Access

Strut prescribes compounded sildenafil and tadalafil, the two most widely studied phosphodiesterase type 5 (PDE5) inhibitors. Sildenafil's efficacy was established in 21 double-blind, placebo-controlled trials involving over 3,000 men, showing improved erections in 56-84% of patients across etiologies [10]. Tadalafil 5 mg daily provides a continuous-dosing option; a 12-week RCT (N=268) demonstrated a mean IIEF-EF domain improvement of 6.0 points versus 1.2 for placebo [11].

The 2018 AUA guideline on erectile dysfunction states: "PDE5 inhibitors are recommended as first-line therapy for ED. Patients should receive education about proper use, including timing, food interactions, and expected onset" [12].

Who fits: Men aged 30-65 with situational or mild-to-moderate organic ED (vascular, psychogenic, or mixed), no unstable cardiovascular disease, and no concurrent nitrate use. The asynchronous model works when ED is the primary complaint and the patient has had a recent physical exam or primary care visit confirming cardiovascular stability.

Who does not fit: Men with ED secondary to undiagnosed diabetes, hypogonadism (testosterone <300 ng/dL), Peyronie's disease, or post-prostatectomy nerve injury need diagnostic workup before empiric PDE5 inhibitor therapy. Concurrent use of nitrates or alpha-blockers at non-stable doses is an absolute contraindication. A questionnaire-only model cannot reliably detect these scenarios without explicit patient disclosure.

Compounding: What the Evidence Supports and Where Gaps Exist

Compounding pharmacies fill a legitimate clinical niche. The FDA recognizes that compounding is necessary when a commercially available product does not meet a patient's specific needs (allergy to an excipient, need for a different dose form, pediatric formulations) [1]. Strut's value proposition rests on combining multiple active ingredients into a single application step.

The gap is clear: combination compounded products have not undergone the bioavailability, stability, and efficacy testing that the FDA requires for new drug applications. A topical formulation's vehicle (the cream, gel, or foam base) affects drug penetration. Two drugs that work independently may interact in unpredictable ways when combined in the same vehicle. This does not mean they are ineffective. It means the evidence supporting the combination is inferred from single-agent trials rather than demonstrated in the specific compounded formulation.

Patients comfortable with this inference, and whose conditions are well-matched to the individual ingredient evidence, represent the ideal Strut user. Patients who want the assurance of FDA-approved combination products should consider commercially available alternatives such as branded topical finasteride (where available) or FDA-approved fixed-dose combination acne products like Epiduo (adapalene/benzoyl peroxide) [13].

Strut vs. Alternatives: How the Model Compares

Several telehealth platforms compete in the same space. Hims and Ro offer both FDA-approved generics and compounded formulations. Keeps focuses primarily on hair loss with standard FDA-approved finasteride and minoxidil. Curology pioneered the compounded multi-ingredient approach for skin care.

Strut differentiates on breadth (covering hair, skin, and ED in one platform) and on its emphasis on compounded combination products. The trade-off: patients using Strut forgo the convenience of picking up a standard generic at a local pharmacy, and they depend on a single compounding pharmacy's supply chain for refills.

A 2021 cross-sectional study of DTC telehealth platforms found that asynchronous consultations resulted in prescriptions 94% of the time, raising concerns about diagnostic rigor in the absence of real-time clinical interaction [14]. This finding applies across platforms, not uniquely to Strut, but it underscores why patient self-selection matters. The model works best for patients who already have an established diagnosis or whose condition is clinically unambiguous.

Cost is a practical differentiator. Strut's pricing for hair loss formulations typically ranges from $35-85/month depending on the specific compound and quantity. Generic oral finasteride 1 mg at a retail pharmacy costs approximately $10-30/month with a GoodRx coupon, while OTC minoxidil 5% solution runs $15-25/month. The compounded combination trades higher cost for the convenience of a single daily application and reduced systemic finasteride exposure.

Safety Considerations and Red Flags

Any patient considering Strut should verify three things before starting treatment.

First, confirm the diagnosis is correct. Hair shedding has over a dozen causes. Acne has mimics. ED can be the first sign of cardiovascular disease, diabetes, or hypogonadism. Patients who have not had a relevant in-person evaluation within the past 12-24 months should see a provider before using any asynchronous telehealth service.

Second, disclose all medications. Drug interactions with PDE5 inhibitors (nitrates, ritonavir, alpha-blockers) are potentially life-threatening. Topical retinoids are Category X in pregnancy [15]. The asynchronous questionnaire model relies entirely on complete patient disclosure.

Third, set outcome expectations using published data. Topical minoxidil 5% typically shows visible results at 4-6 months. Finasteride's peak effect occurs at 12-24 months [2]. Tretinoin requires 8-12 weeks before improvement in acne and 24+ weeks for photoaging benefits [6]. Patients expecting rapid results from any platform will be disappointed.

The Endocrine Society's 2018 testosterone guideline recommends against testosterone therapy in men planning fertility, a consideration that applies if any DTC platform prescribes hormonal agents [16]. Strut's current offerings center on non-hormonal ED treatments, but patients should confirm this at the time of consultation.

Bottom Line: The Ideal Strut Patient

The patient who benefits most from Strut is an adult aged 25-55 with a clearly established, mild-to-moderate case of androgenetic alopecia, inflammatory acne, or erectile dysfunction. This person has had at least one prior in-person clinical evaluation, takes no interacting medications, has no complex comorbidities requiring lab monitoring, and values the convenience of combined-ingredient topical therapy shipped to their home. Patients with Norwood II-IV AGA who want topical finasteride/minoxidil without oral finasteride's systemic DHT suppression represent the single strongest use case based on current evidence [3]. The least suitable patient is anyone with an unconfirmed diagnosis, advanced disease requiring procedural intervention, or a medical history that demands real-time clinical oversight.